MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target'. A key driver of all 'Hallmarks of Cancer', >1M new cancer patients are diagnosed annually with overexpressed Myc protein. MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition & on-target mechanistic profiles, resulting in compelling anti-cancer activity. Ready for Late Lead Optimization, our chemistry is on a clear path to development candidate nomination, underpinned by proprietary structural biology revealing a unique, druggable site, potentially a key breakthrough in drugging Myc. Originally based in Melbourne, Australia, MycRx closed a Series A US-led venture capital round and has restructured as a Delaware corporation, with a growing North American Management team.
View Top Employees from MycRxWebsite | http://mycrxpharma.com |
Revenue | $5 million |
Employees | 15 (5 on RocketReach) |
Founded | 2013 |
Phone | +61 3 9657 0700 |
Technologies |
JavaScript,
HTML,
Twitter
+9 more
(view full list)
|
Industry | Biotechnology Research, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Health Diagnostics, Health Care, Medical, Medical Device |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular MycRx employee's phone or email?
The MycRx annual revenue was $5 million in 2024.
Alison Thistlethwaite is the Director, Operations of MycRx.
5 people are employed at MycRx.
The NAICS codes for MycRx are [3254, 32, 325, 32541].
The SIC codes for MycRx are [283, 28].